# EverQuote, Inc.: financial statements, quarterly

EVER · Nasdaq · CIK 1640428 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ever.md) · [Financials](/companies/ever/financials.md) · [Filings](/companies/ever/filings.md) · [Insiders](/companies/ever/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ever/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [55.0](/filings/0000950170-24-121035.md) | [55.7 d](/filings/0001193125-26-066957.md) | [91.1](/filings/0000950170-25-065862.md) | [117](/filings/0000950170-25-102291.md) | [145](/filings/0001193125-25-264817.md) | [147 d](/filings/0001193125-26-066957.md) | [167](/filings/0001193125-26-206363.md) | [157](/filings/0001193125-26-332775.md) | [174](/filings/0001193125-25-264817.md) | [195 d](/filings/0001193125-26-066957.md) | [191](/filings/0001193125-26-206363.md) | [195](/filings/0001193125-26-332775.md) |
| Cost of revenue | $m | [6.2](/filings/0000950170-24-121035.md) | [5.0 d](/filings/0001193125-26-066957.md) | [5.0](/filings/0000950170-25-065862.md) | [5.0](/filings/0000950170-25-102291.md) | [5.5](/filings/0001193125-25-264817.md) | [5.4 d](/filings/0001193125-26-066957.md) | [5.4](/filings/0001193125-26-206363.md) | [4.8](/filings/0001193125-26-332775.md) | [4.7](/filings/0001193125-25-264817.md) | [4.4 d](/filings/0001193125-26-066957.md) | [4.3](/filings/0001193125-26-206363.md) | [4.4](/filings/0001193125-26-332775.md) |
| Research and development | $m | [6.3](/filings/0000950170-24-121035.md) | [5.9 d](/filings/0001193125-26-066957.md) | [6.8](/filings/0000950170-25-065862.md) | [7.0](/filings/0000950170-25-102291.md) | [8.0](/filings/0001193125-25-264817.md) | [7.6 d](/filings/0001193125-26-066957.md) | [7.5](/filings/0001193125-26-206363.md) | [7.8](/filings/0001193125-26-332775.md) | [7.9](/filings/0001193125-25-264817.md) | [8.3 d](/filings/0001193125-26-066957.md) | [8.5](/filings/0001193125-26-206363.md) | [9.4](/filings/0001193125-26-332775.md) |
| Operating income | $m | [(29.4)](/filings/0000950170-24-121035.md) | [(6.8) d](/filings/0001193125-26-066957.md) | [1.8](/filings/0000950170-25-065862.md) | [6.3](/filings/0000950170-25-102291.md) | [11.7](/filings/0001193125-25-264817.md) | [12.0 d](/filings/0001193125-26-066957.md) | [8.0](/filings/0001193125-26-206363.md) | [14.2](/filings/0001193125-26-332775.md) | [17.5](/filings/0001193125-25-264817.md) | [18.6 d](/filings/0001193125-26-066957.md) | [23.4](/filings/0001193125-26-206363.md) | [23.5](/filings/0001193125-26-332775.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.2](/filings/0000950170-24-121035.md) | [(0.0) d](/filings/0001193125-26-066957.md) | [0.3](/filings/0000950170-25-065862.md) | [0.4](/filings/0000950170-25-102291.md) | [0.7](/filings/0001193125-25-264817.md) | [0.4 d](/filings/0001193125-26-066957.md) | [0.7](/filings/0001193125-26-206363.md) | [0.4](/filings/0001193125-26-332775.md) | [(0.3)](/filings/0001193125-25-264817.md) | [(38.2) d](/filings/0001193125-26-066957.md) | [5.7](/filings/0001193125-26-206363.md) | [5.3](/filings/0001193125-26-332775.md) |
| Net income | $m | [(29.2)](/filings/0000950170-24-121035.md) | [(6.3) d](/filings/0001193125-26-066957.md) | [1.9](/filings/0001193125-25-264817.md) | [6.4](/filings/0001193125-25-264817.md) | [11.6](/filings/0001193125-25-264817.md) | [12.3 d](/filings/0001193125-26-066957.md) | [8.0](/filings/0001193125-26-332775.md) | [14.7](/filings/0001193125-26-332775.md) | [18.9](/filings/0001193125-25-264817.md) | [57.8 d](/filings/0001193125-26-066957.md) | [18.7](/filings/0001193125-26-332775.md) | [19.2](/filings/0001193125-26-332775.md) |
| Diluted EPS | $ per share | [(0.87)](/filings/0000950170-24-121035.md) | not reported | [0.05](/filings/0000950170-25-065862.md) | [0.17](/filings/0000950170-25-102291.md) | [0.31](/filings/0001193125-25-264817.md) | not reported | [0.21](/filings/0001193125-26-206363.md) | [0.39](/filings/0001193125-26-332775.md) | [0.50](/filings/0001193125-25-264817.md) | not reported | [0.51](/filings/0001193125-26-206363.md) | [0.53](/filings/0001193125-26-332775.md) |
| Basic EPS | $ per share | [(0.87)](/filings/0000950170-24-121035.md) | not reported | [0.06](/filings/0000950170-25-065862.md) | [0.18](/filings/0000950170-25-102291.md) | [0.33](/filings/0001193125-25-264817.md) | not reported | [0.22](/filings/0001193125-26-206363.md) | [0.40](/filings/0001193125-26-332775.md) | [0.52](/filings/0001193125-25-264817.md) | not reported | [0.52](/filings/0001193125-26-206363.md) | [0.55](/filings/0001193125-26-332775.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [39.0](/filings/0000950170-23-060247.md) | [38.0](/filings/0000950170-25-026724.md) | [48.6](/filings/0000950170-24-053832.md) | [60.9](/filings/0000950170-24-091761.md) | [82.8](/filings/0000950170-24-121035.md) | [102](/filings/0001193125-26-066957.md) | [125](/filings/0000950170-25-065862.md) | [148](/filings/0000950170-25-102291.md) | [146](/filings/0001193125-25-264817.md) | [171](/filings/0001193125-26-332775.md) | [178](/filings/0001193125-26-206363.md) | [192](/filings/0001193125-26-332775.md) |
| Current assets | $m | [70.1](/filings/0000950170-23-060247.md) | [69.2](/filings/0000950170-25-026724.md) | [95.7](/filings/0000950170-24-053832.md) | [117](/filings/0000950170-24-091761.md) | [140](/filings/0000950170-24-121035.md) | [172](/filings/0001193125-26-066957.md) | [194](/filings/0000950170-25-065862.md) | [209](/filings/0000950170-25-102291.md) | [224](/filings/0001193125-25-264817.md) | [256](/filings/0001193125-26-332775.md) | [257](/filings/0001193125-26-206363.md) | [278](/filings/0001193125-26-332775.md) |
| Total assets | $m | [114](/filings/0000950170-23-060247.md) | [111](/filings/0000950170-25-026724.md) | [135](/filings/0000950170-24-053832.md) | [158](/filings/0000950170-24-091761.md) | [181](/filings/0000950170-24-121035.md) | [211](/filings/0001193125-26-066957.md) | [232](/filings/0000950170-25-065862.md) | [241](/filings/0000950170-25-102291.md) | [256](/filings/0001193125-25-264817.md) | [327](/filings/0001193125-26-332775.md) | [324](/filings/0001193125-26-206363.md) | [341](/filings/0001193125-26-332775.md) |
| Current liabilities | $m | [32.0](/filings/0000950170-23-060247.md) | [29.9](/filings/0000950170-25-026724.md) | [47.1](/filings/0000950170-24-053832.md) | [55.0](/filings/0000950170-24-091761.md) | [60.0](/filings/0000950170-24-121035.md) | [72.6](/filings/0001193125-26-066957.md) | [80.4](/filings/0000950170-25-065862.md) | [69.2](/filings/0000950170-25-102291.md) | [79.5](/filings/0001193125-25-264817.md) | [87.2](/filings/0001193125-26-332775.md) | [81.9](/filings/0001193125-26-206363.md) | [83.4](/filings/0001193125-26-332775.md) |
| Total liabilities | $m | [32.1](/filings/0000950170-23-060247.md) | [30.0](/filings/0000950170-25-026724.md) | [47.1](/filings/0000950170-24-053832.md) | [57.1](/filings/0000950170-24-091761.md) | [62.8](/filings/0000950170-24-121035.md) | [75.2](/filings/0001193125-26-066957.md) | [82.6](/filings/0000950170-25-065862.md) | [71.2](/filings/0000950170-25-102291.md) | [81.1](/filings/0001193125-25-264817.md) | [88.9](/filings/0001193125-26-332775.md) | [83.1](/filings/0001193125-26-206363.md) | [84.2](/filings/0001193125-26-332775.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [81.9](/filings/0000950170-24-121035.md) | [80.9](/filings/0001193125-26-066957.md) | [88.3](/filings/0001193125-25-264817.md) | [101](/filings/0001193125-25-264817.md) | [118](/filings/0001193125-25-264817.md) | [135](/filings/0001193125-26-332775.md) | [150](/filings/0001193125-26-332775.md) | [170](/filings/0001193125-26-332775.md) | [175](/filings/0001193125-25-264817.md) | [238](/filings/0001193125-26-332775.md) | [241](/filings/0001193125-26-332775.md) | [257](/filings/0001193125-26-332775.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.1) d](/filings/0000950170-24-121035.md) | [(0.8) d](/filings/0001193125-26-066957.md) | [10.4](/filings/0000950170-25-065862.md) | [12.4 d](/filings/0000950170-25-102291.md) | [23.6 d](/filings/0001193125-25-264817.md) | [20.1 d](/filings/0001193125-26-066957.md) | [23.3](/filings/0001193125-26-206363.md) | [25.3 d](/filings/0001193125-26-332775.md) | [19.8 d](/filings/0001193125-25-264817.md) | [27.0 d](/filings/0001193125-26-066957.md) | [29.6](/filings/0001193125-26-206363.md) | [24.3 d](/filings/0001193125-26-332775.md) |
| Capital expenditure | $m | [1.0 d](/filings/0000950170-24-121035.md) | [0.9 d](/filings/0001193125-26-066957.md) | [0.8](/filings/0000950170-25-065862.md) | [0.9 d](/filings/0000950170-25-102291.md) | [1.5 d](/filings/0001193125-25-264817.md) | [1.0 d](/filings/0001193125-26-066957.md) | [1.1](/filings/0001193125-26-206363.md) | [1.5 d](/filings/0001193125-26-332775.md) | [1.3 d](/filings/0001193125-25-264817.md) | [1.2 d](/filings/0001193125-26-066957.md) | [1.5](/filings/0001193125-26-206363.md) | [1.6 d](/filings/0001193125-26-332775.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-066957.md) | [19.9](/filings/0001193125-26-206363.md) | [9.1 d](/filings/0001193125-26-332775.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.0](/filings/0000950170-23-060247.md) | [0.0](/filings/0000950170-24-053832.md) | [0.0](/filings/0000950170-24-091761.md) | [0.0](/filings/0000950170-24-121035.md) | [0.0](/filings/0000950170-25-065862.md) | [0.0](/filings/0000950170-25-102291.md) | [37.2](/filings/0001193125-25-264817.md) | [37.7](/filings/0001193125-26-206363.md) | [38.0](/filings/0001193125-26-332775.md) | [37.7](/filings/0001193125-25-264817.md) | [36.9](/filings/0001193125-26-206363.md) | [36.2](/filings/0001193125-26-332775.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.